Business
Result of General Meeting and grant of warrants
Result of General Meeting and grant of warrants.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \n \n RNS Number : 4019Q\n N4 Pharma PLC\n 18 June 2020\n \n \n \n \n N4 Pharma plc\n \n \n (\"N4 Pharma\", the \"Company\" or the \"Group\")\n \n \n \n \n \n Result of General Meeting and grant of warrants\n \n \n \n \n \n N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that at its general meeting held earlier today, all resolutions were duly passed. The results of the proxy voting for the resolutions are set out below. \n \n \n \n \n \n \n \n \n \n \n R\n \n \n esolutio\n \n \n n\n \n \n \n \n \n Votes For*\n \n \n \n \n % of votes cast**\n \n \n \n \n Votes Against\n \n \n \n \n % of votes cast**\n \n \n \n \n Total votes cast**\n \n \n \n \n Votes withheld**\n \n \n \n \n % of issued share capital voted**\n \n \n \n \n \n \n 1. To authorise the Directors to allot securities.\n \n \n \n \n \n 34,120,538\n \n \n \n \n \n \n \n \n \n \n \n 99.988\n \n \n \n \n \n \n 4,147\n \n \n \n \n \n \n 0.0122\n \n \n \n \n \n \n 34,124,685\n \n \n \n \n \n \n \n \n \n \n \n 0\n \n \n \n \n \n \n 22.422\n \n \n \n \n \n \n \n \n 2. To disapply statutory pre-emption rights***.\n \n \n \n \n \n \n \n 34,115,738\n \n \n \n \n \n \n \n \n \n \n \n 99.985\n \n \n \n \n \n \n 5,200\n \n \n \n \n \n \n 0.0152\n \n \n \n \n \n \n 34,120,938\n \n \n \n \n \n \n 3,747\n \n \n \n \n \n \n 22.419\n \n \n \n \n \n \n \n \n \n \n *Votes \"For\" include votes giving the Chairman discretion.\n \n \n ** A 'Vote Withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.\n \n \n *** Proposed as a special resolution.\n \n \n \n \n \n Following the approval of shareholders at today's general meeting, and further to the announcement on 1 June 2020, the Company has now granted warrants over 2,536,562 new ordinary shares to its brokers in respect of the Placing, as announced on 13 May 2020. The warrants are exercisable at a price of 4p until 20 May 2022.\n \n \n \n \n \n Following this grant, the Company has a total of 2,536,562 warrants over ordinary shares outstanding, which represents 1.67 per cent. of the Company's issued share capital as at the date of this announcement.\n \n \n ...